findmyKOL

Jun Li, MD

Enriched profile

Co-Director, Vascular Center and Pulmonary Embolism Response Team (PERT) Program, Harrington Heart & Vascular Institute; Assistant Professor of Medicine, Case Western Reserve University School of Medicine · University Hospitals Harrington Heart & Vascular Institute (Cleveland/Parma, OH); Case Western Reserve University School of Medicine

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Cleveland, OH · Midwest · United StatesSpecialtyInterventional CardiologyFocusCoronary Artery Disease / ACS+1
Active KOLfindmyKOL type: NationalLatest publication2026Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Jun Li is Co-Director, Vascular Center and Pulmonary Embolism Response Team (PERT) Program, Harrington Heart & Vascular Institute; Assistant Professor of Medicine, Case Western Reserve University School of Medicine at University Hospitals Harrington Heart & Vascular Institute (Cleveland/Parma, OH); Case Western Reserve University School of Medicine. OpenAlex indexes 159 publications with 2,766 citations (h-index 22); ClinicalTrials.gov lists 44 registered studies with this person as an investigator.

Data verified 25 Aug 2026

Overview

Updated 16 Oct 2026

Jun Li is Co-Director, Vascular Center and Pulmonary Embolism Response Team (PERT) Program, Harrington Heart & Vascular Institute at University Hospitals Harrington Heart & Vascular Institute (Cleveland/Parma, OH); Case Western Reserve University School of Medicine. The public record shows 159 publications with 2,766 citations (h-index 22), centered on Coronary Artery Disease / ACS, Heart Failure. It also documents an investigator role on 44 registered clinical trials, industry payments reported by 42 companies.

  • Most recent indexed publication: 2026 · Vascular medicine (London, England)
  • Top research focus: Coronary Artery Disease / ACS
  • 44 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 42 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Coronary Artery Disease / ACS9 trialsAngina, Stable7 trialsViral Hepatitis (B/C)6 trialsHepatitis B6 trialsHepatitis B, Chronic5 trialsAngina, Unstable5 trialsHepatitis, Chronic4 trialsGastroesophageal Cancer3 trialsEsophageal Neoplasms3 trialsPulmonary Embolism2 trialsEmbolism2 trialsHepatobiliary Cancer2 trialsDelirium2 trialsPeripheral Arterial Disease2 trialsIschemia2 trialsChronic Limb-Threatening Ischemia2 trialsLung Cancer (NSCLC/SCLC)2 trialsRectal Neoplasms2 trialsNasopharyngeal Carcinoma2 trialsRetinal Vein Occlusion2 trialsHeart Failure2 trialsMyocardial Infarction2 trialsInfarction2 trialsCardiovascular Diseases1 trialLung Diseases1 trialThrombosis1 trialVascular Diseases1 trialRespiratory Tract Diseases1 trialEmbolism and Thrombosis1 trialType 2 Diabetes1 trialPain1 trialLiver Cirrhosis1 trialDiabetes, Gestational1 trialColorectal Cancer1 trialAsthma1 trialAtopic Dermatitis / Eczema1 trialEczema1 trialLeukemia (AML/ALL/CML/CLL)1 trialLeukemia, Promyelocytic, Acute1 trialBronchitis1 trialCognitive Dysfunction1 trialMental Disorders1 trialPostoperative Complications1 trialNeurocognitive Disorders1 trialPathologic Processes1 trialTics1 trialSyphilis1 trialSmall Cell Lung Carcinoma1 trialAdenocarcinoma of Lung1 trialEdema1 trialMacular Edema1 trialLupus (SLE)1 trialST Elevation Myocardial Infarction1 trialPurpura, Thrombocytopenic, Idiopathic1 trialErythema1 trialPurpura1 trialPurpura, Thrombocytopenic1 trial

Research focus

OpenAlex concept fingerprint
Coronary Artery Disease / ACSHeart Failure

Drugs & molecules

across trials, industry payments and publications
Xareltogeneric · RivaroxabanClinical trials—Industry payments55Publications—Eliquisgeneric · ApixabanClinical trials—Industry payments35Publications—Entrestogeneric · Sacubitril / valsartanClinical trials—Industry payments15Publications—NirmatrelvirClinical trials—Industry payments14Publications—Leqviogeneric · InclisiranClinical trials—Industry payments13Publications—Repathageneric · EvolocumabClinical trials—Industry payments13Publications—Verquvogeneric · VericiguatClinical trials—Industry payments8Publications—RimegepantClinical trials—Industry payments6Publications—Arcalystgeneric · RilonaceptClinical trials—Industry payments5Publications—Nexletolgeneric · Bempedoic acidClinical trials—Industry payments5Publications—Camzyosgeneric · MavacamtenClinical trials—Industry payments4Publications—Farxigageneric · DapagliflozinClinical trials—Industry payments4Publications—

Works with

trial sponsors and companies reporting payments
Inquis Medical, Inc.Clinical trials1Industry payments14Medtronic, Inc.Clinical trials—Industry payments333Abbott LaboratoriesClinical trials—Industry payments99Janssen Pharmaceuticals, IncClinical trials—Industry payments55Boston Scientific CorporationClinical trials—Industry payments52Novartis Pharmaceuticals CorporationClinical trials—Industry payments24Pfizer Inc.Clinical trials—Industry payments23Inari Medical, Inc.Clinical trials—Industry payments21E.R. Squibb & Sons, L.L.C.Clinical trials—Industry payments16Atricure, Inc.Clinical trials—Industry payments15Amgen Inc.Clinical trials—Industry payments14AstraZeneca Pharmaceuticals LPClinical trials—Industry payments11Biosense Webster, Inc.Clinical trials—Industry payments10AngioDynamics, Inc.Clinical trials—Industry payments7AbiomedClinical trials—Industry payments6Jun LiClinical trials6Industry payments—Esperion Therapeutics, Inc.Clinical trials—Industry payments5Gilead Sciences, Inc.Clinical trials—Industry payments5ShockWave Medical, IncClinical trials—Industry payments5Stryker CorporationClinical trials—Industry payments5Sun Yat-sen UniversityClinical trials5Industry payments—Merck Sharp & Dohme LLCClinical trials—Industry payments4Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments3Guang'anmen Hospital of China Academy of Chinese Medical SciencesClinical trials3Industry payments—He Eye HospitalClinical trials3Industry payments—Kiniksa Pharmaceuticals International, plcClinical trials—Industry payments3Second Affiliated Hospital, Zhejiang University, School of MedicineClinical trials3Industry payments—Surmodics, Inc.Clinical trials—Industry payments3Terumo Medical CorporationClinical trials—Industry payments3University Hospitals Cleveland Medical CenterClinical trials3Industry payments—

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
159publications

Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.

2,766citations

Total citations across indexed works.

22h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
44clinical trials

Investigator role on registered studies.

View trials ↓
42companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 44 registered studies on ClinicalTrials.gov. The most recent:

All 44 trial records: search, sort and filter.Explore →

Industry payments

Updated 16 Oct 2026

42 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    74.4%
    Statin23%
    Rosuvastatin Calcium80%Atorvastatin Calcium20%
    Part D≥71 patients
    Beta blocker17.3%
    Metoprolol Succinate52%Carvedilol31%Metoprolol Tartrate11%Atenolol6%
    Part D<11 patients

    + 8 more classes in this area

  • Blood & clotting

    25.6%
    Factor Xa inhibitor12%
    Eliquis66%Xarelto34%
    Part D≥22 patients
    P2Y12 inhibitor9.7%
    Clopidogrel100%
    Part D≥49 patients

    + 1 more class in this area

Where care is delivered (Part B)86% facility · 14% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    scai.org/about-us/scai-staff-listing/jun-li-md-fscai

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scai.org ↗
  • LinkedIn

    LinkedIn: linkedin.com/in/junlimd (Endovascular Interventional Cardiologist, Co-Director Vascular Center and PERT, Harrington Heart and Vascular Institute, University Hospitals Cleveland)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
  • Doximity

    Doximity profile: Dr. Jun Li, MD – Parma, OH, Cardiology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    University of Michigan Medical School

    2010
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗
  • Board certified: Internal Medicine

    Cardiovascular Disease, Interventional Cardiology; Registered Physician in Vascular Interpretation (RPVI)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗

Editorial & leadership roles

journal and society appointments
  • Co-Director

    Vascular Center, Harrington Heart & Vascular Institute, University Hospitals

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗
  • Co-Director

    Pulmonary Embolism Response Team (PERT) Program, University Hospitals

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uhhospitals.org ↗
  • Member

    Vascular Disease Council, Society for Cardiovascular Angiography & Interventions (SCAI)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scai.org ↗

Secondary affiliations

appointments beyond the home institution

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.